AstraZeneca in potential $1 billion dollar deal for cardiovascular drug

Share this article:
AstraZeneca announced yesterday that it has entered into a licensing deal worth up to $1 billion with for an anti-inflammatory cardiovascular drug from Alpharetta, Ga.-based pharmaceutical company AtheroGenics.
The product, AGI-1067, is an investigational oral drug for the treatment of atherosclerosis, a disease that can lead to heart attacks and strokes.
AGI-1067 is in phase III development in the Aggressive Reduction of Inflammation Stops Events (ARISE) trial. Study results are due in the second half of 2006.
AstraZeneca said in a statement that it will pay AtheroGenics an upfront fee of $50 million and development and regulatory milestones of up to $300 million with potential further sales-performance related milestones of up to $650 million.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.